Henry Schein, Inc.
HSIC Healthcare Medical Distribution
Henry Schein, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.2 billion, up 4.03% from fiscal 2024. In the quarter to June 2026, revenue grew 6.73%, EPS grew 16.9%, free cash flow grew 140.9% and total debt rose 15.2%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow HSIC
Henry Schein, Inc. (HSIC) EPS (diluted)
Henry Schein, Inc.'s EPS (diluted) for fiscal 2025 was $3.27, up 7.21% from $3.05 in fiscal 2024. Over the twelve months to 30 June 2026 it was $3.43. Over the past ten years it has ranged from $2.57 (fiscal 2017) to $4.65 (fiscal 2019); the current reading is higher than 64% of that period. Henry Schein, Inc. ranks 4th of 10 Medical Distribution companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $3.27 | 7.21% |
| FY2024 | $3.05 | (3.48%) |
| FY2023 | $3.16 | (19.18%) |
| FY2022 | $3.91 | (12.13%) |
| FY2021 | $4.45 | 57.80% |
| FY2020 | $2.82 | (39.35%) |
| FY2019 | $4.65 | 33.24% |
| FY2018 | $3.49 | 35.80% |
| FY2017 | $2.57 | (16.96%) |
| FY2016 | $3.10 | 8.79% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $0.82 | (10.87%) |
| Mar 2026 | $0.92 | 8.24% |
| Dec 2025 | $0.85 | 1.19% |
| Sep 2025 | $0.84 | 20.00% |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| MCK McKesson Corporation compare | $37.37 |
| COR Cencora, Inc. compare | $13.46 |
| CAH Cardinal Health, Inc. compare | $7.23 |
| HSIC Henry Schein, Inc. | $3.43 |
| AHG Akso Health Group Sponsored ADR compare | −$0.55 |
| COSM Cosmos Health Inc. compare | −$0.64 |
| FOCL FocalTherics compare | −$1.03 |
| ACH Accendra Health, Inc. compare | −$3.91 |
| HKPD Cellyan Biotechnology Co., Ltd compare | — |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on HSIC
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement